Review of the use of mirtazapine in the treatment of depression

@article{Benjamin2011ReviewOT,
  title={Review of the use of mirtazapine in the treatment of depression},
  author={S. Benjamin and P. Doraiswamy},
  journal={Expert Opinion on Pharmacotherapy},
  year={2011},
  volume={12},
  pages={1623 - 1632}
}
Introduction: Depression is a heterogeneous illness affecting large numbers of patients with far reaching effects on both psychiatric and medical outcomes as well as quality of life. Knowledge about the different treatment modalities used to treat depression is important to all physicians. Areas covered: This article expands on one such treatment option, mirtazapine. The paper examines this medication's medicinal chemistry, pharmacological properties as well as the efficacy of the medication… Expand
ANTIDEPRESSANTS AND PANIC DISORDER
Several pharmacological approaches showed efficacy for the treatment of patients with panic disorder (PD). However, current guidelines do not provide information about the relative benefit of eachExpand
Is Lithium in a Class of Its Own? A Brief Profile of Its Clinical Use
TLDR
In practice, lithium should be considered a first-line option in bipolar disorder, especially in prophylaxis and when onset of action is not an imperative, but its clinical use has to be tempered against potential side-effects and the need for ongoing monitoring. Expand
When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia
TLDR
The aim of this chapter was to provide an overview of the managing strategies of clozapine-resistant schizophrenia with a particular focus on augmentation strategies aimed to improve efficacy on schizophrenia symptoms. Expand
Mirtazapine-associated movement disorders: A literature review
TLDR
The management of MTZ-associated movement disorders (MDs) should be the MTZ withdrawal, except in RLS that other options are possible, and if available, the prescription of a benzodiazepine may reduce recovery time. Expand
Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study
  • H. Song, W. Bahk, +8 authors K. Min
  • Medicine
  • Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2015
TLDR
This study, as the first clinical trial of generic mirtazapine, demonstrated the efficacy and tolerability of Mirtax for MDD using a single treatment design. Expand
Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial
TLDR
The effect of mirtazapine on hyperemesis gravidarum is investigated while also providing data on the effect of ondansetron in a randomised double-blind placebo-controlled multicentre trial conducted in eight Danish hospitals. Expand
A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome
TLDR
Overall, mirtazapine seems to have a potential benefit in the treatment of patients with IBS-D, particularly those with concomitant psychological symptoms, and further studies are warranted to determine whether these findings are replicated. Expand
Paralytic Ileus Associated With Sodium Valproate: A Case Report
TLDR
This case reportified a case with evidence for MIR-related DITP, with a single agent responsible rather than pharmacokinetic and/or pharmacodynamic drug-drug interaction, and suggests that venlafaxine can be used in place of MIR in cases of D ITP. Expand
Serotonergic drugs for depression and beyond.
TLDR
Various strategies that build upon SERT inhibition provide promise for novel therapeutic approaches to depression, including the possibility of targeting residual symptoms not well treated by Sert inhibition alone, and reducing side effects, such as sexual dysfunction. Expand
Does use of tetracyclic antidepressant—mirtazapine reduce cancer risk in depression patients?
TLDR
A nested case‐control study in Taiwan evaluated the association between risk of cancer and mirtazapine use in depression patients in Taiwan and found no link between use of the drug and cancer risk. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 104 REFERENCES
Efficacy of mirtazapine in clinically relevant subgroups of depressed patients
  • D. Nutt
  • Medicine
  • Depression and anxiety
  • 1998
TLDR
Analysis of the results of placebo‐controlled trials in moderately or severely depressed patients have shown mirtazapine to be effective in clinically important subgroups of depressed patients, particularly anxious patients, patients with sleep disturbance, retarded patients, and agitated patients. Expand
An Open-Label Long-Term Naturalistic Study of Mirtazapine Treatment for Depression in Cancer Patients
TLDR
Relatively low doses of mirtazapine appeared to be safe and effective for treating cancer patients undergoing radiotherapy and/or chemotherapy, and the reduction in the severity of depressive symptoms was maintained until the end of the 24-week treatment period. Expand
Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data
  • S. Kasper
  • Medicine
  • International clinical psychopharmacology
  • 1995
TLDR
It can be concluded that the new antidepressant mirtazapine offers distinct therapeutic benefits for a variety of depressed patients in either in- or outpatient settings. Expand
Improving medication compliance in patients with depression: Use of orodispersible tablets
TLDR
Practical methods of improving compliance in patients with depression with a particular focus on orodispersible tablets (ODTs), which are associated with improved medication compliance compared with traditional tablet formulations. Expand
Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities.
TLDR
The results of this study suggest that patients receiving mirtazapine are less likely to be on anxiolytic/hypnotic agents and that medication costs are less when mirtzapine is used compared with other antidepressants. Expand
Mirtazapine Augmentation in the Treatment of Refractory Depression
Background: Pharmacotherapeutic strategies that target specific actions at multiple neuronal receptors or cellular components may offer a superior approach for treatment of refractory depression.Expand
Mirtazapine versus fluoxetine in the treatment of panic disorder.
  • L. Ribeiro, J. Busnello, +4 authors F. Kapczinski
  • Medicine, Biology
  • Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • 2001
TLDR
Results suggest that mirtazapine has properties that make it attractive for the treatment of panic disorder and shows no significant differences between the two treatment groups in number of panic attacks. Expand
Treating depression with different galenical drug formulations: Does it make a difference? The comparison of mirtazapine fast dissolving formulation (FDT) with conventional mirtazapine tablets (CT)
TLDR
The FDT mirtazapine differed from conventional tablets (CT) not only regarding somewhat less weight increase and overall use preference, but more importantly, regarding better compliance with treatment. Expand
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
TLDR
The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials. Expand
Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.
TLDR
Although mirtazapine is likely to have a faster onset of action than SSRIs, no significant differences were observed at the end of 6 to 12 weeks' treatment and Clinicians should focus on other practically relevant considerations to tailor treatment to best fit the needs of individual patients. Expand
...
1
2
3
4
5
...